Exhaustive Study Notes on Chronic Kidney Disease, Dialysis, and Kidney Transplantation
Overview and Staging of Chronic Kidney Disease (CKD)
Definition: Chronic Kidney Disease (CKD) is a progressive, progressively worsening, and irreversible loss of kidney function.
Differentiation from AKI: Unlike Acute Kidney Injury (AKI), which is often sudden and reversible, CKD develops gradually and cannot be reversed.
Prevalence: Millions of individuals in the United States suffer from CKD across various stages.
Etiology and Leading Causes:
Diabetes mellitus (both Type 1 and Type 2).
Intrinsic kidney diseases (e.g., recurrent pyelonephritis, glomerulonephritis).
Other systemic or neurological diseases affecting renal perfusion and function.
Early Asymptomatic Stage:
In early stages, patients are typically completely asymptomatic and unaware of their declining renal function.
Early detection often occurs incidentally via routine serum chemistry panels showing a decreased Glomerular Filtration Rate (GFR).
Undiagnosed early CKD leads to missed opportunities for early intervention, such as lifestyle modification and discontinuation of nephrotoxic medications (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] used for arthritis).
CKD Staging System (Based on GFR):
Normal GFR: (adjusted for age, gender, and ethnicity).
Stage 1 and Stage 2:
GFR: .
Clinical Status: Often undiagnosed or found incidentally.
Management: Focuses on early risk factor reduction, strict blood pressure control, glycemic control, diet, exercise, and strict avoidance of nephrotoxic agents.
Stage 3a and Stage 3b:
GFR: (GFR drops below ).
Clinical Status: Progression leads to clinical symptoms and early complications. Patients are evaluated with renal and neurological diagnostic studies.
Management: Medication adjustments, aggressive treatment of underlying conditions, and lifestyle modifications.
Stage 4:
GFR: .
Clinical Status: Patient is overtly symptomatic. Manifestations include significant fluid retention, severe electrolyte imbalances, chronic anemia secondary to lack of erythropoietin, hyperphosphatemia, hypocalcemia, and failure to activate Vitamin D.
Management: Aggressive medical management of systemic complications and formal preparation/education for Renal Replacement Therapy (RRT) such as dialysis or kidney transplantation.
Stage 5 (End-Stage Renal Disease - ESRD):
GFR: Less than .
Clinical Status: Severe uremia; kidneys are non-functional.
Management: Requires immediate RRT (hemodialysis, peritoneal dialysis, or kidney transplantation) to sustain life.
Systemic Clinical Manifestations of CKD
Uremia / Uremic Syndrome:
A systemic toxic syndrome caused by the accumulation of waste products (urea, creatinine, phenols, hormones, electrolytes, excess water) in the bloodstream.
Typically occurs when GFR drops below (uremic toxicosis).
Affects virtually every organ system head-to-toe.
Fluid and Urinary Changes:
Early Disease: Mild fluid retention presenting as peripheral edema (e.g., puffy ankles). Early management may utilize diuretic therapy to stimulate remaining functional nephrons and promote diuresis.
Late/Progressive Disease: As nephron damage becomes absolute, diuretic therapy loses efficacy. External fluid removal via dialysis becomes necessary.
Post-Dialysis Initiation: Patients may experience progressive oliguria or complete anuria (zero urine production), though some patients continue to produce small amounts intermittently.
Waste Product Accumulation:
Creatinine: Serum creatinine levels rise inversely as GFR declines. Creatinine is a reliable marker of renal clearance.
Blood Urea Nitrogen (BUN):
BUN increases significantly with kidney failure but is non-specific to renal clearance.
Non-renal factors that elevate BUN include: high-protein diets, strenuous exercise, high metabolic states (e.g., febrile illnesses), corticosteroid therapy, and altered catabolic states.
Metabolic Imbalances:
Carbohydrate Metabolism: Impaired glucose metabolism at the cellular level leads to cellular insulin resistance. Diabetics require altered insulin regimens, while non-diabetic CKD patients may exhibit mild hyperglycemia.
Hyperinsulinemia: High circulating insulin levels due to impaired renal clearance of insulin.
Lipid Metabolism: Hepatic stimulation by high insulin levels increases triglyceride production, leading to hypertriglyceridemia, elevated LDLs, and accelerated atherosclerosis.
Electrolyte and Acid-Base Imbalances:
Hyperkalemia:
Inability of the kidneys to excrete potassium leads to severe retention.
Electrocardiogram (ECG) changes (e.g., tall peaked T-waves) typically emerge at serum potassium levels of .
Hyperkalemia is a medical emergency that can induce fatal cardiac dysrhythmias.
Treatment includes restriction of dietary potassium and administration of potassium-lowering agents.
Hyponatremia:
Frequently a dilutional hyponatremia caused by massive vascular fluid retention rather than an absolute sodium deficit.
Treatment focuses on fluid removal (diuresis or dialyzer ultrafiltration) rather than sodium administration.
Hyperphosphatemia and Hypocalcemia:
The failure of injured kidneys to activate Vitamin D prevents GI absorption of calcium, resulting in hypocalcemia.
Serum calcium and phosphate maintain an inverse relationship; high phosphate retention drives down serum calcium.
Decreased serum calcium triggers Parathyroid Hormone (PTH) release, which stimulates osteoclasts to pull calcium from the skeletal system, leading to bone resorption and osteomalacia.
Hypermagnesemia:
Excretion of magnesium is impaired. Excess levels can lead to cardiac dysrhythmias, depressed deep tendon reflexes, and respiratory failure.
Metabolic Acidosis:
Results from the inability of impaired nephrons to excrete metabolic acids (specifically hydrogen ions) combined with defective reabsorption and regeneration of bicarbonate ().
Patients often adapt to a chronic, mild metabolic acidotic state.
Severe acidosis induces Kussmaul respirations (deep, rapid breathing pattern) to compensate by blowing off carbon dioxide ().
Hematologic Manifestations:
Anemia:
Primary cause: Decreased production of erythropoietin (EPO) by damaged renal tubular cells, leading to reduced bone marrow RBC production.
Hemodialysis-related blood loss: Mechanical lysis of RBCs within the dialyzer circuit, blood trapped in lines, and frequent venous blood sampling.
GI Blood Loss: Chronic physiological stress increases mucosal erosion and ulceration.
Nutritional Deficiencies: Depleted iron stores and dialytic loss of folic acid.
Bleeding Tendency: Uremic toxins impair platelet aggregation and function, creating qualitative platelet defects and increasing bleeding risks.
Infection Risk: Altered immune response, hyperglycemia, and invasive access devices (hemodialysis catheters, PD catheters) increase susceptibility to systemic infection.
Cardiovascular Manifestations:
High circulating calcium-phosphate levels cause vascular and soft tissue calcification, leading to vessel stiffness, loss of endothelial elasticity, and accelerated Cardiovascular Disease (CVD).
Hypertension: Both a primary cause and a direct consequence of CKD; exacerbated by sodium and fluid retention.
Left Ventricular Hypertrophy (LVH):
Chronic fluid overload and elevated systemic vascular resistance force the left ventricle to work harder, resulting in muscular hypertrophy.
Progressive LVH leads to dilated cardiomyopathy and left-sided heart failure.
Cardiac Dysrhythmias: Triggered by hyperkalemia, hypocalcemia, hypermagnesemia, and myocardial ischemia secondary to narrowed coronary arteries.
Uremic Pericarditis: Accumulation of uremic toxins causes pericardial inflammation, which can progress to pericardial effusion and cardiac tamponade. A pericardial friction rub may be auscultated.
Gastrointestinal Manifestations:
Stomatitis: Uremic breakdown of oral mucosa causing painful inflammation and mouth ulcerations, making swallowing painful.
Uremic Fetor: A characteristic urine-like or ammonia-like odor on the breath due to salivary urea breakdown.
Anorexia: Loss of appetite caused by toxic buildup.
Gastritis and Peptic Ulcer Disease: High incidence of gastric mucosal erosion secondary to chronic physiological stress; managed prophylactically with Proton Pump Inhibitors (PPIs, e.g., IV or oral pantoprazole).
Neurological Manifestations:
Toxin Accumulation Effects: Irritability, fatigue, lethargy, apathy, and impaired concentration.
The "Dialysis Cycle Effect": Patients experience severe symptom swings—feeling lethargic and toxic prior to dialysis, fatigued/nauseated immediately following treatment, followed by a brief window of improved well-being before uremic toxins accumulate again.
Advanced Encephalopathy: Lethargy, stupor, confusion, hallucinations, seizures, and coma (requires emergency RRT or end-of-life care).
Peripheral Neuropathy: Paresthesias described as numbness, tingling, or pinprick sensations in extremities; muscle cramping; and restless leg syndrome (involuntary leg movements at rest).
Motor Dysfunction: Foot drop, severe muscle weakness and atrophy, loss of deep tendon reflexes, muscle twitching, nocturnal leg cramps, and asterixis.
Asterixis: A characteristic involuntary flapping tremor of the hands when extended, caused by toxic metabolites crossing the blood-brain barrier.
Integumentary Manifestations:
Pruritus: Severe, refractory itching caused by cutaneous calcium-phosphate deposits and uremic toxins (uremic frost) crystallizing on the skin.
Management: Keep fingernails trimmed short to prevent skin excoriation and secondary bacterial infections.
Reproductive Manifestations:
Libido reduction and infertility occur in both sexes.
Females: Amenorrhea (cessation of menses).
Males: Low sperm counts (oligospermia) and erectile dysfunction.
Pregnancy on dialysis carries severe maternal-fetal risks and requires intensive, high-frequency dialysis schedules.
Psychosocial Manifestations:
Significant anxiety, clinical depression, and grief surrounding loss of kidney function, loss of independence, and lifestyle restriction.
Interprofessional Management of CKD
Diagnostic Workup and Referrals:
Comprehensive Health History and Physical Examination.
Serial monitoring of serum GFR, creatinine, BUN, and urine albumin-to-creatinine ratio.
Early referral to a Nephrologist for disease management and preparation for RRT.
Superimposed Acute Kidney Injury (Acute-on-Chronic):
Patients with existing CKD are highly vulnerable to secondary AKI from nephrotoxic insults (e.g., radiocontrast dye, NSAIDs, hypovolemia).
Immediate removal of the insulting agent and supportive care can return the patient to their baseline CKD stage rather than allowing permanent loss of function.
Medical and Lifestyle Interventions (Stages 1–4):
Tight blood pressure control via antihypertensive medications.
Glycemic control in diabetic patients.
Fluid volume management: Diuretics in early stages; fluid restrictions in advanced stages.
Nutritional Therapy:
Potassium Restriction: Avoid high-potassium foods to prevent fatal dysrhythmias.
Phosphorus/Phosphate Restriction:
Restrict dietary phosphorus to approximately once ESRD or advanced CKD develops.
Limit dairy products, aged cheeses, nuts, and meats. Phosphate binders may be prescribed to be taken with meals.
Fluid Restriction: Based on daily fluid output and clinical evidence of overload.
Iron Supplementation:
Oral iron supplements are difficult to absorb through the GI tract; co-administration with citrus juices (Vitamin C) enhances uptake.
IV iron infusions are common for severe anemia. IV iron requires continuous monitoring during administration due to high risk of adverse/hypersensitivity reactions similar to blood product transfusions.
Folic Acid: Supplementation is required because folic acid is dialyzed out during RRT.
Protein Management:
Normal protein intake is maintained during Stages 1 through 3.
Hemodialysis patients require reduced/controlled protein intake to prevent excess nitrogenous waste (BUN) accumulation.
PD Exception: Peritoneal Dialysis patients lose substantial amounts of protein through the peritoneal membrane during drainage; therefore, PD patients require a high-protein diet.
Pharmacological Considerations and Toxicity Risk:
Impaired renal clearance causes drug accumulation and high toxicity risk for renally cleared medications.
Digoxin: High risk for digoxin toxicity; requires precise monitoring.
Antidiabetic Agents and Opioids: Require dosage reductions.
Antibiotics (Renal Dosing):
Dosages must be adjusted based on calculated GFR.
Timing with Dialysis: If an antibiotic (e.g., Vancomycin) is dialyzable, the dose must be held until after the hemodialysis session. Administering it before HD results in the machine clearing the drug from the blood before it reaches therapeutic levels.
Peritoneal Dialysis (PD)
Mechanism of Action:
Utilizes the patient's own peritoneal membrane as a semipermeable membrane for solute exchange and fluid removal via osmosis and diffusion.
Access is established by surgically placing a peritoneal catheter (e.g., Tenckhoff catheter) into the abdominal peritoneal cavity.
Aseptic Technique:
Strict aseptic technique must be maintained by the patient or caregiver during all connections and exchanges to prevent life-threatening peritonitis.
Requires a mandatory 5-to-7-day structured training program prior to home management.
The Three Phases of a PD Exchange (The Cycle):
Inflow (Fill):
Approximately of sterile, prescribed dialysate solution is infused into the peritoneal cavity via gravity or cycler over about 10 minutes.
Temperature Requirement: Solution must be pre-warmed (takes ~15 minutes). Infusing cool or room-temperature fluid causes severe abdominal cramping and visceral hypothermia.
Note: Pediatric or small-stature patients start with smaller fill volumes () to gradually stretch the peritoneal cavity.
Dwell:
The fluid remains in the peritoneal cavity for a prescribed duration (e.g., 20 to 30 minutes, or several hours depending on the protocol).
Osmotic gradient is created primarily by dextrose in the dialysate, which pulls waste products and fluid across the membrane.
Drain:
Takes approximately 15 to 30 minutes.
Effluent drains out of the peritoneal cavity via gravity into a waste bag.
Patient positioning changes may be required to facilitate complete drainage.
Effluent appearance: Should be clear and pale yellow (resembling urine).
PD Regimens:
Automated Peritoneal Dialysis (APD):
Uses an automated cycler machine while the patient sleeps.
Performs multiple cycles (e.g., 6 cycles over 8 hours) with automated fill, dwell, and drain phases.
Features safety alarms for tube kinking or line pressure alterations.
Continuous Ambulatory Peritoneal Dialysis (CAPD):
Manual exchanges performed 4 to 6 times throughout the day (every 6 to 8 hours).
Advantages of PD:
Physiologically smoother fluid and solute removal without the violent metabolic "swings" or severe hemodynamic drops seen in traditional hemodialysis.
Better preserves remaining baseline renal function and provides patient independence.
Eliminates the need for specialized home water treatment systems (uses pre-packaged solution).
Complications of Peritoneal Dialysis:
Exit Site Infection:
Characterized by erythema, tenderness, and purulent discharge at the catheter exit site.
Requires immediate antibiotic treatment to prevent progression to tunnel infection or peritonitis.
Peritonitis:
Major, life-threatening complication caused by contamination during exchange or exit site/tunnel infection.
Manifestations: Severe abdominal pain, rebound tenderness, abdominal guarding, rigid board-like abdomen, cloudy dialysate effluent, fever, chills, malaise, nausea, and vomiting.
Management: Obtain effluent specimen for Gram stain, culture, and sensitivity; initiate systemic and intraperitoneal antibiotics immediately.
Consequence: Repeated episodes cause peritoneal membrane scarring/adhesions, rendering the patient permanently ineligible for PD (requiring conversion to hemodialysis).
Hernias: Increased intra-abdominal pressure from high dwell volumes leads to abdominal or inguinal hernias. Managed conservatively or with surgical repair.
Lower Back Pain: Extra intra-abdominal weight causes increased lumbar curvature; managed with abdominal binders.
Pulmonary Complications: Large dwell volumes displace the diaphragm upward, restricting lung expansion and predisposing to atelectasis, bronchitis, and pneumonia.
Bleeding: Minor bloody effluent is expected with initial catheter insertion, but persistent bloody effluent indicates active internal bleeding.
Hyperglycemia and Weight Gain: High dextrose content in dialysate is systemically absorbed, causing hyperinsulinemia, weight gain, and difficulty maintaining glycemic control.
Hemodialysis (HD)
Mechanism of Action:
Involves diverting patient blood out of the body through an extracorporeal circuit containing a artificial semipermeable membrane (dialyzer).
Requires rapid, high-volume blood flow and high-capacity vascular access.
Types of Vascular Access:
Arteriovenous Fistula (AVF):
Surgical creation of a direct anastomosis between a native artery and vein (usually in the forearm).
The high-pressure arterial flow "arterializes" the vein, making it thick-walled and large-caliber.
Maturation Time: Requires at least 3 months to mature before it can be cannulated for HD.
Arteriovenous Graft (AVG):
Synthetic bridge material implanted to connect an artery and a vein.
Healing Time: Requires 2 to 4 weeks before use.
Disadvantages: Higher rate of infection and thrombosis compared to native AVFs.
Access Assessment:
Thrill: A continuous palpable vibration felt over the access site.
Bruit: A continuous swooshing sound heard via stethoscope over the access site.
Presence of both thrill and bruit confirms access patency.
Access Safety Rules:
NEVER perform blood pressure measurements, venipunctures, or IV insertions on the extremity containing an AVF or AVG.
Label the extremity clearly to prevent loss of life-sustaining vascular access.
Steal Syndrome (Distal Ischemia):
Complication caused by the access "stealing" arterial blood from the distal extremity.
Manifestations: Ischemic pain distal to the access site, cold skin, numbness, tingling, diminished pulses, and prolonged capillary refill.
Temporary Vascular Access (HD Catheter / Trialysis):
Double-lumen or triple-lumen central venous catheter placed in the internal jugular or femoral vein.
Used for acute kidney failure, drug overdoses, or as a bridge while an AVF/AVG matures.
High risk for central line infections and accidental dislodgement (severe hemorrhage emergency).
Strict Access Policy: Non-dialysis nurses must never touch, flush, or use a hemodialysis catheter unless specifically trained or explicitly ordered to access a designated 3rd auxiliary port.
Pre-Hemodialysis Clinical Assessment:
Fluid Status Evaluation:
Measure today's pre-dialysis weight and compare it to the patient's post-dialysis dry weight from the previous session.
Formula: .
Conversion: .
Example: Current weight , Dry weight = () removal goal.
Physical Assessment: Check peripheral edema, auscultate heart sounds (for new murmur) and lung sounds (for crackles), evaluate access patency (thrill/bruit), measure baseline temperature (screen for infection), and check blood pressure.
Vital Signs: Monitored every 30 to 60 minutes throughout the HD procedure.
HD Schedule:
Standard Outpatient Protocol: 3 to 4 hours per session, 3 days per week (e.g., Monday/Wednesday/Friday or Tuesday/Thursday/Saturday).
Alternative Options: Nocturnal hemodialysis or specialized home hemodialysis.
Complications of Hemodialysis:
Hypotension (Most Common Complication):
Caused by rapid fluid removal into the extracorporeal circuit and transient hypovolemia.
Manifestations: Lightheadedness, syncope, dizziness, nausea, vomiting, vision changes ("seeing stars"), seizures, or angina.
Management: Reduce ultrafiltration rate, reinfuse normal saline boluses, place patient in Trendelenburg position, and administer pre-dialysis vasopressors (e.g., midodrine) as ordered.
Muscle Cramps: Caused by rapid fluid and electrolyte shifts; managed by slowing ultrafiltration and administering fluid boluses.
Blood Loss: Caused by incomplete blood rinse-back, line separation, or accidental needle dislodgement from the fistula.
Hepatitis: Risk of viral hepatitis transmission if single-use dialyzers or supplies are improperly reused.
NCLEX Priority Emergency Management for Severe Hyperkalemia:
Step 1: Calcium Gluconate IV: Administered immediately to protect the heart by stabilizing the myocardial cell membrane ("glues down heart muscle") to prevent fatal dysrhythmias.
Step 2: IV Regular Insulin (+ Dextrose): Drives potassium out of the bloodstream and back into the intracellular space.
Continuous Renal Replacement Therapy (CRRT)
Indication:
Designed for hemodynamically unstable patients in critical care units (e.g., ICU patients with septic shock, trauma, or multiorgan failure) who cannot tolerate the rapid fluid and blood pressure shifts of standard 3-to-4-hour hemodialysis.
Key Features:
Slow, continuous 24-hour treatment process.
Blood pump speeds are significantly slower than standard HD.
Solute removal occurs primarily by convection alongside ultrafiltration.
Anticoagulation Requirements:
Continuous circulation through the extracorporeal circuit requires anticoagulation to prevent filter clotting.
Utilizes systemic Heparin or local Citrate anticoagulation (paired with a Calcium infusion to counteract systemic citrate effects).
CRRT Effluent Monitoring:
Ultrafiltrate/waste output should be clear to pale yellow.
Critical Alarm: If the ultrafiltrate turns pink or bloody, it indicates a structural rupture of the dialyzer membrane. The treatment must be stopped immediately to prevent massive blood loss.
Nursing Interventions:
Serial serum electrolyte measurements every 4 to 8 hours.
Strict hourly Intake & Output (I&O) measurements.
Daily weights.
Meticulous vascular catheter site care using chlorhexidine scrub to prevent Catheter-Associated Bloodstream Infections (CLABSI).
Kidney Transplantation
Overview:
The definitive treatment for End-Stage Renal Disease (ESRD), offering superior survival rates and quality of life compared to lifelong dialysis.
Deceased donor (cadaver) average wait time is 2 to 5 years.
One-Year Graft Survival Rates: ~90% for deceased donors; ~95% for living donors.
Recipient Exclusion Criteria:
Morbid obesity (unable to self-care or excessive surgical risk).
Active tobacco smoking, alcohol abuse, or active illicit drug abuse.
Active, advanced malignancy.
Refractory, untreated cardiovascular disease or severe heart failure.
Unresolved chronic infections.
Documented Non-Compliance: History of missing medical appointments, failing to fill prescriptions, or skipping dialysis sessions (indicates inability to adhere to mandatory post-transplant immunosuppressive regimens).
Donor Types and Surgical Considerations:
Living Donor: Surgical nephrectomy performed 1 to 2 hours prior to recipient surgery. Allows minimal organ "cold time" and immediate graft function.
Deceased (Cadaver) Donor: Brain-dead donor kept on mechanical ventilation and cardiovascular support. Cold preservation time preferred under 24 hours (can be preserved up to 72 hours).
Paired Organ Donation: Match trade system used when a willing living donor is immunologically incompatible with their intended recipient.
Surgical Placement: The recipient's native non-functioning kidneys are usually left in place (where they shrivel up over time) unless infected or polycystic. The new donor kidney is placed extraperitoneally in the iliac fossa and connected to local vascular structures and the bladder.
Post-Operative Nursing Management (Recipient):
Primary Goal: Maintain fluid and electrolyte balance and preserve renal perfusion.
Expected Post-Op Diuretic Phase (Autodiuresis):
The new kidney produces massive amounts of urine immediately upon reperfusion ().
Driven by fluid overload, urea accumulation, and new renal perfusion.
Requires strict 1:1 hourly fluid replacement and close monitoring for hyponatremia and hypokalemia.
Critical Warning Sign: A sudden drop in urine output is the primary indicator of hyperacute/acute rejection, renal artery thrombosis, or catheter obstruction.
Types of Transplant Rejection:
Hyperacute Rejection:
Occurs within minutes to hours post-transplantation.
Antibody-mediated reaction.
Manifestations: High fever, chills, severe pain at the transplant site, immediate cessation of urine output.
Treatment: Immediate surgical removal of the rejected kidney.
Acute Rejection:
Occurs days to months post-transplantation.
Cell-mediated immune response.
Manifestations: Rising serum creatinine and BUN, dropping GFR, decreased urine output, fever, hypertension, weight gain, and graft tenderness.
Treatment: Reversible with increased doses of immunosuppressants (e.g., IV corticosteroid pulses, monoclonal antibodies).
Chronic Rejection:
Occurs over months to years.
Irreversible scarring and vascular injury to the graft.
Manifestations: Progressive decline in kidney function mimicking chronic renal failure.
Treatment: Supportive care; patient eventually returns to dialysis or seeks another transplant.
Complications of Lifelong Immunosuppressive Therapy (Corticosteroids, Tacrolimus):
Infection Risk: High risk of opportunistic viral, fungal, and bacterial infections (e.g., CMV, Epstein-Barr Virus, Herpes Simplex Virus, Varicella-Zoster, Pneumonia, UTIs).
Aseptic (Avascular) Necrosis of Joints: Chronic steroid use damages microcirculation to bone tissue, leading to necrosis of major joints ( hips and knees).
Peptic Ulcer Disease (PUD): High risk for severe GI bleeding.
Steroid-Induced Hyperglycemia / Diabetes Mellitus.
Cataracts and Dyslipidemia.
Increased Malignancy Risk: Suppressed immune system fails to perform tumor cell surveillance, leading to higher rates of cancers.